Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) FCF Margin (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed FCF Margin for 7 consecutive years, with 41.44% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 5987.0% to 41.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 19.83% through Dec 2025, up 23389.0% year-over-year, with the annual reading at 19.83% for FY2025, 23389.0% up from the prior year.
  • FCF Margin for Q4 2025 was 41.44% at Madrigal Pharmaceuticals, down from 27.5% in the prior quarter.
  • The five-year high for FCF Margin was 27.5% in Q3 2025, with the low at 922.78% in Q2 2024.